BRAF and acinar cell carcinoma: In addition, a patient with acinar cell carcinoma in the tail of the pancreas and BRAF V600E mutation obtained 8 months of PFS by combined target therapy with dabrafenib and trametinib, but the patient received chemotherapy for more than 5 years before the target therapy.